Navigation Links
Pharmatek's Highly-Potent and Cytotoxic (HP/C) Facility Positions It as Industry Leader in Development and Manufacturing of HP/C Compounds

Pharmatek Demonstrates Effectiveness Of New Highly-Potent And Cytotoxic (HP/C) Facility Through Airborne Particulate Testing.

SAN DIEGO, May 5 /PRNewswire/ -- Pharmatek Laboratories, Inc. - a premier pharmaceutical chemistry development organization supporting the pharmaceutical industry - has completed comprehensive airborne particulate testing of its new state-of-the-art facility for the development and manufacturing of highly-potent and cytotoxic compounds.

"The testing results of our HP/C facility allows Pharmatek to expand our development and manufacturing services to include highly potent and cytotoxic compounds, and do it in the safest possible way," says Tim Scott, President of Pharmatek Laboratories. "The results from extensive facility testing exceeded Pharmatek's expectations for the safe handling of category 4 compounds on a 5 band scheme."

The monitoring results exceeded the testing goals and demonstrate Pharmatek's engineering controls and practices are effective at controlling airborne particulates down to 0.1ug/m3 levels.

"Combined with the facility engineering controls, significantly lower particulate levels are achieved when respiratory protection factors and process specific enclosure systems are taken into account. The specific operator breathing zone results, on an actual time-weighted basis, demonstrate that Pharmatek can safely handle highly-potent and cytotoxic compounds," says Kevin Rosenthal, Director of Manufacturing at Pharmatek Laboratories.

The facility was specifically designed for the development and manufacturing of HP/C drug products. The dedicated facility includes 18,000 sq. ft. of analytical, formulation development and manufacturing lab space. In addition to the development space, there are two certified and validated high-containment manufacturing suites designed with soft-wall enclosure systems that give flexibility to meet the demands of each client's project.

About Pharmatek Laboratories, Inc.

Pharmatek Laboratories Inc. is a pharmaceutical chemistry development company providing full-service pharmaceutical chemistry product development for the pharmaceutical industry. Pharmatek focuses on bringing client compounds from discovery to the clinic with services that include compound selection, analytical development, preformulation testing, formulation development, GMP manufacturing, and stability storage and testing.

Statements contained in this media release which are not historical facts may constitute forward-looking statements. All forward-looking statements are subject to risks and uncertainties which could cause actual results to differ from those projected including sales forecasts and strategic expansion. The trademarks Pharmatek, Pharmatek Laboratories, Inc., Hot Rod Chemistry and Pharmatek Formulation Screening are all property of Pharmatek Laboratories, Inc. Additional information about Pharmatek Laboratories may be obtained at the Web site or by calling 858-805-6383.

    Company Contact:
    Ryan Lane, Marketing Coordinator
    Pharmatek Laboratories, Inc.
    (858) 805-6383 x284

Available Topic Expert(s): For information on the listed expert(s), click appropriate link.

Jeffrey A. Bibbs

Available Topic Expert(s): For information on the listed expert(s), click appropriate link.

Timothy M. Scott

SOURCE Pharmatek Laboratories, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. New Data Offers Insights Into the Potential Role for TYKERB(R) (Lapatinib) in Non-Cytotoxic Chemotherapy-Based Treatment Regimens
2. CEL-SCI Secures Manufacturing Facility for Multikine Cancer Drug
3. Biodel Inc. Completes Enrollment of Two Pivotal Phase III Clinical Trials of VIAject(TM) and Plans Manufacturing Facility for VIAject(TM)
4. Molecular Biometrics Hires Denny Sakkas, PhD Renowned Yale Embryologist and International Thought-Leader, as Chief Scientific Officer; Opening U.S. Research Facility
5. CEL-SCI Expects to Take Delivery of New Manufacturing Facility on October 8, 2008
6. Isogen Launches Major New Facility to Address Global Biopharma Demand
7. Micromet Expands Committed Equity Financing Facility to $75 Million
8. Keeping the Data Center Clean: ATEN Launches Industry-First KVM Switches with Antimicrobial Nanocoating to Protect Products from Bacteria Surviving on Surfaces
9. U.S. Meat Industry Will Respond to World Cancer Research Fund Report
10. Wedgewood Introduces Refresh(TM) Exchange-Program: Free Exchange of Expired Veterinary Compounded Medications Solves Key Industry Problem
11. EntreMed to Present at The New York Society of Security Analysts Industry Conference
Post Your Comments:
(Date:6/23/2016)... 23, 2016 Research and Markets ... Market by Type (Organic Chemical (Sugar, Petrochemical, Glycerin), Inorganic ... Coating, Parenteral) - Global Forecast to 2021" report ... The global pharmaceutical excipients market is projected to ... of 6.1% in the forecast period 2016 to 2021. ...
(Date:6/23/2016)... Research and Markets has announced the ... 2016 - Forecast to 2022" report to their offering. ... up to date financial data derived from varied research sources ... with potential impact on the market during the next five ... comprises of sub markets, regional and country level analysis. The ...
(Date:6/23/2016)... 23, 2016 Bracket , a leading clinical ... generation clinical outcomes platform, Bracket eCOA (SM) 6.0, at ... 26 – 30, 2016 in Philadelphia , ... Outcome Assessment product of its kind to fully integrate with ... Bracket eCOA 6.0 is a flexible platform for electronic clinical ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... June 25, 2016 , ... ... recover from injury. Recently, he has implemented orthobiologic procedures as a method for ... is one of the first doctors to perform the treatment. Orthobiologics are substances ...
(Date:6/24/2016)... ... 2016 , ... A recent article published June 14 on E ... goes on to state that individuals are now more comfortable seeking to undergo not ... as calf and cheek reduction. The Los Angeles area medical group, Beverly Hills Physicians ...
(Date:6/24/2016)... ... June 24, 2016 , ... Marcy was in a crisis. Her son James, eight, was ... his family verbally and physically. , “When something upset him, he couldn’t control his emotions,” ... He would throw rocks at my other children and say he was going to kill ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... micro-osteoperforation for accelerated orthodontic treatment. Dr. Cheng has extensive experience with all areas ... , AcceleDent, and accelerated osteogenic orthodontics. , Micro-osteoperforation is a revolutionary adjunct ...
(Date:6/24/2016)... ... June 24, 2016 , ... People across the U.S. are sharpening ... Talker Award, an essay contest in which patients and their families pay tribute to ... at the 2016 National Society of Genetic Counselors (NSGC) Annual Education Conference (AEC) this ...
Breaking Medicine News(10 mins):